GlassScriptPhysician profile
Eddie K Lam
NPI 1518969971
$3,499.95
in general payments reported to CMS, 2019-2025
22 companies · $680 in 2025
The $680 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $839 · 2020: $337 · 2021: $79.68 · 2022: $213 · 2023: $931 · 2024: $419 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,030.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $739.89 | 2019-2024 | Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $395.12 | 2023-2025 | |
| Lilly USA, LLC | $337.41 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $301.95 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $284.72 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $215.02 | 2019-2023 | Farxiga |
| Verona Pharma, INC. | $203.32 | 2025 | Ohtuvayre |
| Novartis Pharmaceuticals Corporation | $200.42 | 2019-2025 | |
| Novo Nordisk INC | $165.57 | 2019-2025 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $150.54 | 2019-2020 | |
| Abbvie INC. | $86.38 | 2020-2023 | |
| Kowa Pharmaceuticals America, INC. | $81.77 | 2019-2025 | Zoryve |
| Sumitomo Pharma America, INC. | $52.60 | 2023-2025 | Gemtesa |
| Corcept Therapeutics | $48.96 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $44.07 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $43.71 | 2019 | |
| Pfizer INC. | $41.66 | 2019 | |
| Radius Health, INC. | $27.34 | 2019 | |
| Dexcom, INC. | $23.37 | 2024 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $19.74 | 2025 | |
| Sunovion Pharmaceuticals INC. | $19.40 | 2019 | |
| Ironwood Pharmaceuticals, INC | $16.99 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eddie Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.